24-month clinical outcomes of a treat-and-extend regimen with ranibizumab for wet age-related macular degeneration in a real life setting
To evaluate the clinical effectiveness and analyze the outcomes of a treat-and-extend (T&E) treatment regimen with ranibizumab for wet age-related macular degeneration (ARMD) in real life clinical settings ove... (Source: BMC Ophthalmology)
Source: BMC Ophthalmology - April 27, 2017 Category: Opthalmology Authors: Athanasios Vardarinos, Nitin Gupta, Raazia Janjua, Abigail Iron, Theo Empeslidis and Konstantinos T. Tsaousis Source Type: research

Comparison of Conbercept with Ranibizumab for the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion.
CONCLUSION: Intravitreal injection of conbercept is shown to be safe and effective for the treatment of ME secondary to BRVO, based on 6-month follow-up data. PMID: 28441077 [PubMed - as supplied by publisher] (Source: Current Eye Research)
Source: Current Eye Research - April 25, 2017 Category: Opthalmology Authors: Li F, Sun M, Guo J, Ma A, Zhao B Tags: Curr Eye Res Source Type: research

Ten-Year Follow-Up after Bilateral Submacular Neovascular Membrane Removal in a Case of Autosomal Recessive Bestrophinopathy
Herein, we report the case of an 8-year-old girl who presented in December 2000 with a submacular neovascular membrane in the right eye, with a clinical diagnosis of Best disease. At that time, she underwent pars plana vitrectomy (PPV) with removal of the subretinal choroidal neovascularization (CNV). Her vision improved from 20/200 to 20/25. Four years later, a new CNV developed in the other eye. Initially, she underwent unsuccessful photodynamic therapy. As her vision worsened, she underwent a second, this time successful, PPV with membrane removal in the left eye, with vision improving to 20/30. Ten years later, she ret...
Source: Case Reports in Ophthalmology - April 24, 2017 Category: Opthalmology Source Type: research

Long-term release and stability of pharmaceutical proteins delivered from solid lipid implants.
Abstract Solid lipid implants (SLIs) prepared by twin-screw (tsc) extrusion represent a promising technology platform for the sustained release of pharmaceutical proteins. In this work, we report on two aspects, long-term release and stability of released protein. First, SLIs were produced by tsc-extrusion containing the low melting triglyceride H12 and the high melting triglyceride Dynasan D118. Two different proteins available in a freeze-dried matrix containing hydroxypropyl-β-cyclodextrine (HP-β-CD) were incorporated into the lipid matrix: a monoclonal antibody (mAb) from the IgG1 class and the fab-f...
Source: European Journal of Pharmaceutics and Biopharmaceutics - April 22, 2017 Category: Drugs & Pharmacology Authors: Vollrath M, Engert J, Winter G Tags: Eur J Pharm Biopharm Source Type: research

Intravitreal Ranibizumab in Diabetic Macular Edema: Long-Term Outcomes.
In conclusion, randomized clinical trials showed that RBZ was superior to laser in DME treatment, providing excellent long-term visual outcomes. Frequent injections were necessary in most of the patients to properly control DME and maximize the visual benefits. PMID: 28427066 [PubMed - in process] (Source: Developments in Ophthalmology)
Source: Developments in Ophthalmology - April 21, 2017 Category: Opthalmology Tags: Dev Ophthalmol Source Type: research

Intravitreal Aflibercept in Diabetic Macular Edema: Long-Term Outcomes.
Authors: Introini U, Casalino G Abstract For decades, macular laser photocoagulation has been the standard of care in the treatment of diabetic macular edema (DME). With the relatively recent advent of anti-vascular endothelial growth factor (VEGF) agents, DME treatment has entered a new era. VEGF is a well-known pro-angiogenic and pro-permeability factor involved in the pathogenesis of DME. VEGF blockade has proven remarkably effective at reducing DME and improving visual acuity (VA) in eyes with center involved DME causing VA loss in several randomized controlled trials (RCTs). Intravitreal aflibercept, ranibizum...
Source: Developments in Ophthalmology - April 21, 2017 Category: Opthalmology Tags: Dev Ophthalmol Source Type: research

Practical Lessons from Protocol I for the Management of Diabetic Macular Edema.
Authors: Mukkamala L, Bhagat N, Zarbin MA Abstract Protocol I, a multicenter randomized clinical trial, compared the visual outcomes of patients treated with 0.5 mg intravitreal ranibizumab with either prompt or deferred (by 24 weeks laser), 4 mg intravitreal triamcinolone with prompt laser, or sham injection with prompt laser for the treatment of center-involving diabetic macular edema (DME). A total of 854 adult patients with type I or II diabetes and any level of non-proliferative diabetic retinopathy or proliferative retinopathy with adequate panretinal photocoagulation, with best-corrected visual acuity (BCVA)...
Source: Developments in Ophthalmology - April 21, 2017 Category: Opthalmology Tags: Dev Ophthalmol Source Type: research

Practical Lessons from Protocol T for the Management of Diabetic Macular Edema.
Authors: Mukkamala L, Bhagat N, Zarbin M Abstract PURPOSE: To review the results of Diabetic Retinopathy Clinical Research Network Protocol T, as applied to clinical practice. METHODS: Review of major publications reporting the results of Protocol T, a randomized single-masked (in year-1 only), multicenter clinical trial comparing aflibercept, bevacizumab, and ranibizumab as treatment option for center-involving diabetic macular edema (DME). The main outcome measures were change in visual acuity (VA), central subfield thickness (CST) on optical coherence tomography, cost effectiveness, burden of care, and safet...
Source: Developments in Ophthalmology - April 21, 2017 Category: Opthalmology Tags: Dev Ophthalmol Source Type: research

Anti-Vascular Endothelial Growth Factor Injections: The New Standard of Care in Proliferative Diabetic Retinopathy?
Authors: Li X, Zarbin MA, Bhagat N Abstract For decades, panretinal photocoagulation (PRP) has been the standard of care for the treatment of proliferative diabetic retinopathy (PDR). The relatively recent advent of anti-vascular endothelial growth factor (VEGF) formulations for intravitreal injection has provided a fresh perspective on PDR treatment, especially in eyes with concurrent diabetic macular edema (DME). The anti-VEGF agent ranibizumab has demonstrated a potentially protective effect on eyes with DME in terms of progression to PDR in the RIDE/RISE trials, as has aflibercept in the VIVID/VISTA trials. In ...
Source: Developments in Ophthalmology - April 21, 2017 Category: Opthalmology Tags: Dev Ophthalmol Source Type: research

Clinical relevance of aqueous vascular endothelial growth factor levels in polypoidal choroidal vasculopathy
Conclusion: Vascular endothelial growth factor level demonstrated a negative correlation with baseline subfoveal choroidal thickness and was associated with response to anti-VEGF treatment. These findings suggest that VEGF has a variable contribution to the pathogenesis of polypoidal choroidal vasculopathy depending on choroid thickness. (Source: RETINA)
Source: RETINA - April 21, 2017 Category: Opthalmology Tags: Original Study Source Type: research

Role of additional dexamethasone for the management of persistent or recurrent neovascular age-related macular degeneration under ranibizumab treatment
Conclusion: This pilot study indicates combined therapy to delay retreatment in patients with persistent/recurrent neovascular age-related macular degeneration and an overall reduction in required ranibizumab retreatments compared with ranibizumab monotherapy with consistent functional outcomes. (Source: RETINA)
Source: RETINA - April 21, 2017 Category: Opthalmology Tags: Original Study Source Type: research

Serum levels of vascular endothelial growth factor before and after intravitreal injection of ranibizumab or conbercept for neovascular age-related macular degeneration
Conclusion: Conbercept significantly decreased serum VEGF level 1 day and 1 week after injection, but this effect was not sustained for 1 month. In contrast, ranibizumab had no significant effect on serum VEGF concentration changes. The reduction in serum VEGF by conbercept may affect its systemic safety profile. (Source: RETINA)
Source: RETINA - April 21, 2017 Category: Opthalmology Tags: Original Study Source Type: research

Long-Term Anatomical and Functional Outcomes in Patients with Ischemic Central Retinal Vein Occlusion Treated with Anti-Vascular Endothelial Growth Factor Agents
Conclusions: Our study showed that anti-VEGF treatment was effective in patients with ischemic CRVO, since it reduces macular edema and maintains or improves VA in the long term (24-month follow-up). It is worthy of note that in a small proportion of patients (13.3%) peripheral ischemia progressed to macular ischemia over time. In cases where macular ischemia is present, anti-VEGF treatment does not seem to offer any improvement in VA.Ophthalmic Res (Source: Ophthalmic Research)
Source: Ophthalmic Research - April 20, 2017 Category: Opthalmology Source Type: research

Corrigendum
The authors of “Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration” (Ophthalmology 2016;123:2545-2553) would like to add the following financial statement to their acknowledgements section: (Source: Ophthalmology)
Source: Ophthalmology - April 19, 2017 Category: Opthalmology Tags: Corrigendum Source Type: research

Intravitreal anti-VEGF treatment for choroidal neovascularization secondary to punctate inner choroidopathy
ConclusionsCNV development is a frequent complication of PIC. Intravitreal anti-VEGF therapy seems to be safe and effective for PIC-related CNV. (Source: International Ophthalmology)
Source: International Ophthalmology - April 19, 2017 Category: Opthalmology Source Type: research

Classification of diabetic macular oedema using ultra-widefield angiography and implications for response to anti-VEGF therapy
Conclusions UWFA facilitates the detection of peripheral ischaemia, which is associated with a significant proportion of DMO. While this group of DMO responded well to anti-VEGF therapy, it remains to be determined whether addressing the peripheral ischaemia may reduce recurrence. (Source: British Journal of Ophthalmology)
Source: British Journal of Ophthalmology - April 18, 2017 Category: Opthalmology Authors: Xue, K., Yang, E., Chong, N. V. Tags: Original articles - Clinical science Source Type: research

Erratum to: The Clinical Effectiveness of Ranibizumab Treat and Extend Regimen in nAMD: Systematic Review and Network Meta-Analysis
(Source: Advances in Therapy)
Source: Advances in Therapy - April 17, 2017 Category: Drugs & Pharmacology Source Type: research

Ranibizumab Injection as Primary Treatment in Patients with Retinopathy of Prematurity
To investigate the anatomic outcomes and influencing factors of ranibizumab in the treatment of retinopathy of prematurity (ROP). (Source: Ophthalmology)
Source: Ophthalmology - April 13, 2017 Category: Opthalmology Authors: Qiujing Huang, Qi Zhang, Ping Fei, Yu Xu, Jiao Lyu, Xunda Ji, Jie Peng, Yi-an Li, Peiquan Zhao Source Type: research

Relation between macular morphology and treatment frequency during twelve months with ranibizumab for diabetic macular edema
ConclusionThe retinal thickness in the inferior subfield predicts the treatment frequency during the first year in eyes with DME treated with PRN IVR injections. (Source: PLoS One)
Source: PLoS One - April 13, 2017 Category: Biomedical Science Authors: Yuki Mori Source Type: research

Outcomes of switching treatment to aflibercept in patients with macular oedema secondary to central retinal vein occlusion refractory to ranibizumab
ConclusionsAflibercept is an effective alternative treatment for macular oedema secondary to CRVO refractory to ranibizumab. Good anatomical and functional result can be achieved with few injections. The maintenance of these results after 6  months is yet to be investigated. (Source: International Ophthalmology)
Source: International Ophthalmology - April 12, 2017 Category: Opthalmology Source Type: research

Nurse-led ranibizumab intravitreal injections in wet age-related macular degeneration: a literature review.
Conclusion Practice innovation is an example of a quality, innovation, productivity and prevention process. Role expansion, in which specialist ophthalmic nurses deliver intravitreal injections, has been shown to be economical, safe and effective. It enables timely delivery of the service, thereby preventing irreversible blindness for individuals with wet AMD. PMID: 28399772 [PubMed - in process] (Source: Nursing Standard)
Source: Nursing Standard - April 12, 2017 Category: Nursing Authors: Gregg E Tags: Nurs Stand Source Type: research

Long-Term Follow-Up of Polypoidal Choroidal Vasculopathy Secondary to Angioid Streaks Treated by Intravitreal Aflibercept and Ranibizumab
Conclusion: The treat-and-extend protocol with intravitreal aflibercept or ranibizumab with or without PDT is effective and safe for PCV secondary to AS.Case Rep Ophthalmol 2017;8:221 –231 (Source: Case Reports in Ophthalmology)
Source: Case Reports in Ophthalmology - April 11, 2017 Category: Opthalmology Source Type: research

Impact of intravitreal pharmacotherapies including antivascular endothelial growth factor and corticosteroid agents on diabetic retinopathy
Purpose of review:Diabetic retinopathy is common and increasing in prevalence. Pharmacologic management of diabetic macular edema (DME) has improved tremendously over the last decade with the use of two families of intravitreally administered medications: antivascular endothelial growth factor-specific agents and corticosteroids. Clinical evaluation of these pharmaceuticals has demonstrated that they can have a substantial impact on diabetic retinopathy severity levels and the underlying retinal vasculature itself. Recent findings:Phase 3 trials employing ranibizumab, aflibercept, and fluocinolone acetonide enrolling eyes...
Source: Current Opinion in Ophthalmology - April 11, 2017 Category: Opthalmology Tags: RETINAL, VITREOUS AND MACULAR DISORDERS: Edited by Brandon G. Busbee and John W. Kitchens Source Type: research

Role of cytokines and treatment algorithms in retinopathy of prematurity
This article reviews recent studies related to these questions and other trials for severe ROP. Recent findings:Imaging studies identify biomarkers of risk (plus disease, stage 3 ROP, and ROP in zone I). Intravitreal bevacizumab or ranibizumab are reported effective in treating aggressive posterior ROP in small series. Recurrences and effects on myopia vary among studies. Use of anti-VEGF agents affects cytokines in the infant blood and reduces systemic VEGF for up to 2 months, raising potential safety concerns. The effects of treatment vary based on infant size and are not comparable. Evidence for most studies is not hig...
Source: Current Opinion in Ophthalmology - April 11, 2017 Category: Opthalmology Tags: TRANSLATIONAL RESEARCH: Edited by Jason Hsu and Sunir Garg Source Type: research

Bilateral Neovascular Age-Related Macular Degeneration: Comparisons between First and Second Eyes
Conclusions: A large proportion of patients are asymptomatic at diagnosis of second-eye nAMD. Early intervention following earlier detection of nAMD in the second eye may lead to improved clinical outcomes.Ophthalmologica (Source: Ophthalmologica)
Source: Ophthalmologica - April 11, 2017 Category: Opthalmology Source Type: research

Incidence and Timing of the First Recurrence in Neovascular Age-Related Macular Degeneration: Comparison Between Ranibizumab and Aflibercept
Journal of Ocular Pharmacology and Therapeutics , Vol. 0, No. 0. (Source: Journal of Ocular Pharmacology and Therapeutics)
Source: Journal of Ocular Pharmacology and Therapeutics - April 6, 2017 Category: Opthalmology Source Type: research

[Retinal Vein Occlusion - Which Treatment When?]
Authors: Bajor A, Pielen A, Danzmann L Abstract According to the latest findings, macular oedema due to retinal vein occlusion is best treated safely and effectively with near-term intravitreal anti-VEGF therapy (aflibercept, bevacizumab [off label], ranibizumab). After an initial upload of 3 monthly injections of anti-VEGF, the decision on re-injection should be based on OCT (rather than on visual acuity). After initial monthly injections, the "pro-re-nata" (PRN) and the "treat-and-extend" regimens have been predominantly used in the further course of therapy. Taking into account the side ...
Source: Klinische Monatsblatter fur Augenheilkunde - April 5, 2017 Category: Opthalmology Tags: Klin Monbl Augenheilkd Source Type: research

Predictive factors of better outcomes by monotherapy of an antivascular endothelial growth factor drug, ranibizumab, for diabetic macular edema in clinical practice
Abstract: Intravitreal ranibizumab (IVR) has been approved for treating diabetic macular edema (DME), and is used in daily clinical practice. However, the treatment efficacies of IVR monotherapy in real-world clinical settings are not well known. The medical records of 56 eyes from 38 patients who received their first IVR for DME between April 2014 and March 2015, and were retreated with IVR monotherapy as needed with no rescue treatment, such as laser photocoagulation, were retrospectively reviewed. The clinical course, best-corrected visual acuity (BCVA), and fundus findings at baseline, before the initial IVR injection...
Source: Medicine - April 1, 2017 Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research

Vitreous hemorrhage as an early sign of acute bacterial endophthalmitis following intravitreal ranibizumab injection
ConclusionsVitreous hemorrhage may be an atypical presentation of acute bacterial endophthalmitis occurring after intravitreal injection. (Source: International Ophthalmology)
Source: International Ophthalmology - April 1, 2017 Category: Opthalmology Source Type: research

[Intravitreal ranibizumab therapy for choroidal neovascularization secondary to pathological myopia].
CONCLUSIONS: Intravitreal ranibizumab is an effective therapy in pathological myopia. Some patients experience deterioration of visual acuity despite of treatment. Orv. Hetil., 2017, 158(15), 579-586. PMID: 28393596 [PubMed - in process] (Source: Orvosi Hetilap)
Source: Orvosi Hetilap - April 1, 2017 Category: Journals (General) Authors: Lukács R, Sándor G, Resch M, Szabó A, Barcsay G, Ecsedy M, Szepessy Z, Nagy ZZ, Papp A Tags: Orv Hetil Source Type: research

Self ‐retaining weighted thermoplastic ampoule holder for aflibercept and ranibizumab vials
(Source: Clinical and Experimental Ophthalmology)
Source: Clinical and Experimental Ophthalmology - April 1, 2017 Category: Opthalmology Authors: WengOnn Chan, Melissa Shields, Paul Sia, Robert Casson Tags: Letter to the Editor Source Type: research

Combination of Anti-VEGF and Laser Photocoagulation for Diabetic Macular Edema: A Review.
Authors: Distefano LN, Garcia-Arumi J, Martinez-Castillo V, Boixadera A Abstract Diabetic macular edema (DME) is the most common cause of vision loss in diabetic patients. Thirty years ago, the Early Treatment Diabetic Retinopathy Study (ETDRS) demonstrated that focal/grid laser photocoagulation reduces moderate vision loss from DME by 50% or more; thus, macular photocoagulation became the gold standard treatment for DME. However, with the development of anti-VEGF drugs (bevacizumab, ranibizumab, and aflibercept), better outcomes were obtained in terms of visual acuity gain and decrease in macular thickness in some...
Source: Journal of Ophthalmology - March 31, 2017 Category: Opthalmology Tags: J Ophthalmol Source Type: research

Switch to Aflibercept in Diabetic Macular Edema Patients Unresponsive to Previous Anti-VEGF Therapy.
Authors: Mira F, Paulo M, Henriques F, Figueira J Abstract Purpose. The aim was to evaluate the efficacy of aflibercept in patients with diabetic macular edema (DME) unresponsive to prior anti-VEGF therapy. Methods. Retrospective review of DME unresponsive to previous anti-VEGF switched to aflibercept with 3 months of follow-up. Changes in best correct visual acuity (BCVA), central retinal thickness (CRT), and frequency of injections were analyzed. The percentage of subjects who had ≥20/40 (logMAR equivalent 0.3) and ≤20/200 (logMAR equivalent 1) was evaluated. Results. A total of 32 eyes from 26 patients wer...
Source: Journal of Ophthalmology - March 31, 2017 Category: Opthalmology Tags: J Ophthalmol Source Type: research

Retinal Vein Occlusions.
Authors: Jonas JB, Monés J, Glacet-Bernard A, Coscas G Abstract Retinal vein occlusions (RVOs) have been defined as retinal vascular disorders characterized by dilatation of retinal veins with retinal and subretinal hemorrhages, macular edema, and a varying degree of retinal ischemia. Retinal angiography, either as fluorescein and indocyanine green (ICG) angiography or in the form of optical coherence tomography (OCT)-based angiography, is essential for the diagnosis and assessment of the prognosis of RVOs. It allows the differentiation of diverse types of RVOs, such as perfused or nonperfused, as well as th...
Source: Developments in Ophthalmology - March 31, 2017 Category: Opthalmology Tags: Dev Ophthalmol Source Type: research

The vascularization process after intravitreal ranibizumab injections for aggressive posterior retinopathy of prematurity
Conclusion: These results showed that retinal vascularization following intravitreal ranibizumab was completed after a delay in patients with AP-ROP. Further studies are necessary to evaluate when and how vascularization occurs after intravitreal anti-vascular endothelial growth factor treatments.RESUMO Objetivo: Avaliar o processo de vasculariza ção da retina após injeção intravítrea de ranibizumab aplicada em crianças com retinopatia da prematuridade posterior agressiva (AP-ROP). Métodos: Vinte e seis olhos de 13 crianças com AP-ROP que receberam 0,25 mg de r...
Source: Arquivos Brasileiros de Oftalmologia - March 30, 2017 Category: Opthalmology Source Type: research

[Response to aflibercept in patients with fibrovascular pigment epithelial detachment refractory to ranibizumab in exudative age-related macular degeneration].
Authors: Tran TH, Dumas S, Coscas F PMID: 28336285 [PubMed - as supplied by publisher] (Source: Journal Francais d Ophtalmologie)
Source: Journal Francais d Ophtalmologie - March 27, 2017 Category: Opthalmology Tags: J Fr Ophtalmol Source Type: research

Visual acuity outcomes of ranibizumab treatment in pathologic myopic eyes with macular retinoschisis and choroidal neovascularization
Conclusion: Improvement of visual acuity is delayed and reduced after 3 months intravitreal ranibizumab in eyes with MRS and myopic choroidal neovascularization compared to eyes without MRS. More ranibizumab injections are needed in eyes with MRS to gain comparable BCVA at Month 12. (Source: RETINA)
Source: RETINA - March 24, 2017 Category: Opthalmology Tags: Original Study Source Type: research

Serum vascular endothelial growth factor after bevacizumab or ranibizumab treatment for retinopathy of prematurity
Conclusion: Serum VEGF levels in patients with Type 1 ROP were suppressed for 2 months after treatment with IVB, and VEGF levels were less affected after IVR treatment. Further studies are warranted to investigate the long-term effects of VEGF changes in ROP patients. (Source: RETINA)
Source: RETINA - March 24, 2017 Category: Opthalmology Tags: Original Study Source Type: research

RANIBIZUMAB FOR MACULAR EDEMA AFTER BRANCH RETINAL VEIN OCCLUSION: One Initial Injection Versus Three Monthly Injections
Purpose: To compare the 12-month-efficacy of 1 initial intravitreal ranibizumab injection (IVR) followed by pro re nata (PRN) dosing with that of three initial monthly IVR followed by PRN dosing in patients with macular edema (ME) after branch retinal vein occlusion. Design: Prospective, interventional study. Methods: Of 81 eyes, 42 received 1 initial IVR injection (1+PRN group) and 39 eyes received 3 monthly IVRs (3+PRN). Pro re nata injections were performed when fovea exudative changes were evident. Results: At Month 12, the visual acuity (VA) changes from baseline were −0.245 ± 0.227 and −0.287 &p...
Source: RETINA - March 24, 2017 Category: Opthalmology Tags: Original Study Source Type: research

Comparison of intravitreal injection of ranibizumab versus laser therapy for zone ii treatment-requiring retinopathy of prematurity
Conclusion: Although IVR appears to regress ROP to certain levels and continue to promote the vascularization of peripheral retinal vessels, a substantial proportion of infants developed recurrence of ROP after a single-dose IVR. Therefore, IVR is not recommended as a single-dose monotherapy for Zone II treatment-requiring ROP. (Source: RETINA)
Source: RETINA - March 24, 2017 Category: Opthalmology Tags: Original Study Source Type: research

Aqueous humor cytokine levels as biomarkers of disease severity in diabetic macular edema
Purpose: To determine whether aqueous cytokine levels correlate with disease severity in diabetic macular edema. Methods: A prospective cross-sectional study of 49 adults with diabetes mellitus, centre-involving diabetic macular edema and central subfield macular thickness ≥310 μm on spectral domain optical coherence tomography. Clinical examination and aqueous sampling were carried out before an initial injection of ranibizumab. Multiplex immunoassay of sample was carried out for vascular endothelial growth factor, placental growth factor, transforming growth factor beta, intercellular adhesion molecule-1, interleu...
Source: RETINA - March 24, 2017 Category: Opthalmology Tags: Original Study Source Type: research

DOME-SHAPED MACULA IN MYOPIC EYES: Twelve-Month Follow-up
Conclusion: Dome-shaped macula is a condition associated with myopic eyes that seems to remain stable over time in terms of vision and macular profiles. It is often associated with chronic SRF, for which no effective treatment is current available. However, SRF does not seem to be a significant cause of visual impairment. (Source: RETINA)
Source: RETINA - March 24, 2017 Category: Opthalmology Tags: Original Study Source Type: research

Intravitreal Dexamethasone Implant versus Intravitreal Ranibizumab for the Treatment of Macular Edema Secondary to Retinal Vein Occlusion in a Chinese Population
Conclusions: Intravitreal injection of Ozurdex and ranibizumab can effectively control ME secondary to RVO and increase a patient's BCVA. The advantages of Ozurdex are fewer injections and longer efficacy, while the advantages of ranibizumab include fewer side effects.Ophthalmic Res (Source: Ophthalmic Research)
Source: Ophthalmic Research - March 23, 2017 Category: Opthalmology Source Type: research

Comparison of Progression Rate of Retinal Pigment Epithelium Loss in Patients with Neovascular Age-Related Macular Degeneration Treated with Ranibizumab and Aflibercept.
Conclusions. There seems to be a linear progression rate of RPE loss in patients treated with ranibizumab as well as in patients with aflibercept. No significant increase of progression rate was found after switch to aflibercept. PMID: 28316836 [PubMed - in process] (Source: Journal of Ophthalmology)
Source: Journal of Ophthalmology - March 23, 2017 Category: Opthalmology Tags: J Ophthalmol Source Type: research

Early and Long-term Responses to Anti –Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema: Analysis of Protocol I Data
We are pleased that Dr Ophir agrees with the importance of our retrospective analysis of pooled data from the DRCR.net Protocol I study1,2 and the need for the development of alternate approaches to diagnosis and treatment of diabetic macular edema (DME). In his letter, Dr Ophir re-emphasizes the modest gains received by many patients from intensive treatment and monitoring with ranibizumab plus prompt focal/grid laser treatment in the Protocol I study.2,3 In response to our statement that an effective treatment algorithm for DME is uncertain in this group of suboptimal responders, he offers a systematic evidence-based app...
Source: American Journal of Ophthalmology - March 22, 2017 Category: Opthalmology Authors: Victor H. Gonzalez, Joanna Campbell, Nancy M. Holekamp, Szil árd Kiss, Anat Loewenstein, Albert J. Augustin, Julia Ma, Allen C. Ho, Vaishali Patel, Scott M. Whitcup, Pravin U. Dugel Tags: Correspondence Source Type: research

Reply
We are pleased that Dr Ophir agrees with the importance of our retrospective analysis of pooled data from the DRCR.net Protocol I study1,2 and the need for the development of alternate approaches to diagnosis and treatment of diabetic macular edema (DME). In his letter, Dr Ophir re-emphasizes the modest gains received by many patients from intensive treatment and monitoring with ranibizumab plus prompt focal/grid laser treatment in the Protocol I study.2,3 In response to our statement that an effective treatment algorithm for DME is uncertain in this group of suboptimal responders, he offers a systematic evidence-based app...
Source: American Journal of Ophthalmology - March 22, 2017 Category: Opthalmology Authors: Victor H. Gonzalez, Joanna Campbell, Nancy M. Holekamp, Szil árd Kiss, Anat Loewenstein, Albert J. Augustin, Julia Ma, Allen C. Ho, Vaishali Patel, Scott M. Whitcup, Pravin U. Dugel Tags: Correspondence Source Type: research

[Ranibizumab tachyphylaxis in a case of macular edema related to central retinal vein occlusion: Lasting effectiveness of switching to aflibercept].
Authors: Gambrelle J, Robinet A PMID: 28318715 [PubMed - as supplied by publisher] (Source: Journal Francais d Ophtalmologie)
Source: Journal Francais d Ophtalmologie - March 21, 2017 Category: Opthalmology Tags: J Fr Ophtalmol Source Type: research

Comparison of the 12-Month Outcomes of Intravitreal Ranibizumab between Two Angiographic Subtypes of Polypoidal Choroidal Vasculopathy
Conclusions: The outcomes of IVR may be different between two angiographic subtypes of PCV.Ophthalmologica (Source: Ophthalmologica)
Source: Ophthalmologica - March 21, 2017 Category: Opthalmology Source Type: research

Re: Wells et  al.: Aflibercept, Bevacizumab, or Ranibizumab for diabetic macular edema: two year results from a comparative effectiveness randomized clinical trial (Ophthalmology. 2016;123:1351-1359)
The Diabetic Retinopathy Clinical Research Network (DRCR.net) has made useful observations regarding diabetic retinopathy, including their most recent manuscript.1 However, I have questions about their classification of and conclusions about diabetic macular edema (DME). In an earlier manuscript, DRCR.net concluded that “little evidence exists that characteristics of DME described by the terms focal and diffuse help to explain variation in visual acuity or response to treatment” and that “it is unresolved whether a concept of focal and diffuse DME will prove clinically useful despite frequent usage of the...
Source: Ophthalmology - March 20, 2017 Category: Opthalmology Authors: Pradeep Venkatesh Tags: Correspondence Source Type: research